practice changes for use of immunotherapy in nsclc: q&a
Published 6 years ago • 61 plays • Length 5:31Download video MP4
Download video MP3
Similar videos
-
1:02:36
practice changes for use of immunotherapy in nsclc
-
1:00:44
practical application of recent clinical data for immunotherapy in nsclc
-
7:01
actual use of pembrolizumab and chemotherapy in nsclc
-
5:00
implications for pembrolizumab in nsclc
-
5:25
immunotherapy in lung cancer
-
10:36
patient selection for immunotherapy in la nsclc
-
8:48
upfront use of immunotherapy for ncslc
-
8:01
upfront immunotherapy for nsclc
-
5:27
combined immunotherapy and chemotherapy for nsclc
-
11:38
immunotherapy for management of stage 3b nsclc
-
6:36
patient selection for upfront immunotherapy in nsclc - o
-
8:44
upfront immunotherapy for pd-l1 nsclc
-
5:43
duration of upfront immunotherapy for nsclc
-
0:36
dr. camidge on the fda approval of pembrolizumab for squamous nsclc
-
6:56
upfront immunotherapy for nsclc
-
1:22
dr. bauml on the use of immunotherapy in oligometastatic nsclc
-
5:10
the role of immunotherapy in squamous nsclc
-
8:14
approaching non-driver stage iv nsclc
-
2:34
dr. langer on practice-changing pacific data in stage iii nsclc